Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04133168 · ClinicalTrials.gov registry record · NA
Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 458
- Enrollment target
NCT04133168 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 458 participants.
The verdict
NCT04133168, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 458 participants
- Enrollment target
Study Summary
To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation (AF).
Interventions
- DEVICE Boston Scientific Cardiac Cryoablation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2023-08-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04133168
The ClinicalTrials.gov registry entry for NCT04133168 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Boston Scientific Cardiac Cryoablation System is the first listed.
NCT04133168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04133168 about?
NCT04133168 is a clinical study titled "Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation". To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation (AF).
What is the current status of trial NCT04133168?
This trial is currently completed. It is a NA study. The enrollment target is 458 participants. The study started on 2020-06-24. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT04133168?
The interventions under investigation include: Boston Scientific Cardiac Cryoablation System (DEVICE).
Who is sponsoring clinical trial NCT04133168?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.